We are live on
!
Find out more
TA
Tamarack Advisers Portfolio holdings
AUM
$2.12M
1-Year Est. Return
58.09%
This Fund
S&P 500
This Quarter
Est. Return
+33.49%
1 Year Est. Return
-58.09%
3 Year Est. Return
-46.51%
5 Year Est. Return
+44.44%
10 Year Est. Return
–
AUM
$359M
AUM Growth
+$95.1M
(+36%)
Cap. Flow
+$16.4M
Cap. Flow
% of AUM
4.56%
Top 10 Holdings %
Top 10 Hldgs %
56.75%
Holding
42
New
11
Increased
10
Reduced
11
Closed
9
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ICU Medical
ICUI
|
+$13.3M |
| 2 |
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
|
+$10.2M |
| 3 |
UnitedHealth
UNH
|
+$10M |
| 4 |
Lantheus
LNTH
|
+$9.91M |
| 5 |
Labcorp
LH
|
+$8.86M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AtriCure
ATRC
|
+$16.3M |
| 2 |
Viatris
VTRS
|
+$8.1M |
| 3 |
MDRX
Veradigm Inc. Common Stock
MDRX
|
+$7.84M |
| 4 |
Medtronic
MDT
|
+$7.19M |
| 5 |
CHNG
Change Healthcare Inc. Common Stock
CHNG
|
+$6.99M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 90% |
| 2 | Technology | 5.35% |
| 3 | Materials | 1.59% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Plexus
PLXS
$6.72B
| $4.66M | 1.3% |
+66,000
| New | +$4.1M |
|
|
MSON
27
DELISTED
Misonix Inc
MSON
| $4.37M | 1.22% |
322,041
+123,241
| +62% | +$1.51M |
|
28
Teva Pharmaceuticals
TEVA
$40.8B
| $3.08M | 0.86% |
+250,000
| New | +$2.83M |
|
29
Natera
NTRA
$38.3B
| $2.99M | 0.83% |
+60,000
| New | +$2.41M |
|
30
SI-BONE Inc
SIBN
$788M
| $1.68M | 0.47% |
105,200
-101,800
| -49% | -$1.6M |
|
|
31
CALL
Teva Pharmaceuticals
TEVA
$40.8B
| $1.63M | 0.45% |
+6,500
| New | +$73.5K |
|
32
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$790B
| $896K | 0.25% |
+4,000
| New | +$1.17M |
|
33
PUT
State Street SPDR NYSE Technology ETF
XNTK
$2.06B
| $274K | 0.08% |
+2,000
| New | +$176K |
|
34
Becton Dickinson
BDX
$45.6B
| – | – |
-15,375
| Closed | -$3.45M |
|
35
eHealth
EHTH
$42.2M
| – | – |
-10,000
| Closed | -$1.41M |
|
36
Edwards Lifesciences
EW
$49.6B
| – | – |
-30,000
| Closed | -$1.89M |
|
37
Integer Holdings
ITGR
$4.12B
| – | – |
-10,000
| Closed | -$629K |
|
38
Merck
MRK
$322B
| – | – |
-94,320
| Closed | -$6.92M |
|
39
Pfizer
PFE
$143B
| – | – |
-105,400
| Closed | -$3.26M |
|
40
Insulet
PODD
$11.5B
| – | – |
-5,000
| Closed | -$828K |
|
|
CHNG
41
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| – | – |
-700,000
| Closed | -$6.99M |
|
|
PGNX
42
DELISTED
Progenics Pharmaceuticals Inc
PGNX
| – | – |
-1,100,000
| Closed | -$4.18M |
|
Similar funds
SCM
LBC
ICM
LCMP
GIP
STC
GC
DU
Tamarack Advisers's Q2 2020 Portfolio in Review
As of Q2 2020, Tamarack Advisers held 42 positions worth $359M, up 36% from $264M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Tamarack Advisers deployed $16.4M of net new capital in Q2 2020, opening 11 new positions and adding to 10 existing holdings. Its largest new stake was GW Pharmaceuticals Plc American Depositary Shares: 90,000 shares worth $11M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, down from 91% a quarter earlier, followed by Technology and Materials.
On the sell side, the largest reduction was AtriCure, an estimated $16.3M trimmed.
- Tamarack Advisers's largest Q2 2020 buy was GW Pharmaceuticals Plc American Depositary Shares: 90,000 shares worth $11M.
- Tamarack Advisers added most to ICU Medical in Q2 2020, an estimated $13.3M increase.
- Tamarack Advisers's biggest Q2 2020 reduction was AtriCure, cutting an estimated $16.3M.
- Tamarack Advisers fully exited Change Healthcare Inc. Common Stock in Q2 2020, selling an estimated $6.99M.
- Tamarack Advisers's ten largest holdings make up 57% of its $359M portfolio in Q2 2020.
- Tamarack Advisers opened 11 new positions and closed 9 in Q2 2020.
- Tamarack Advisers's portfolio value rose 36% quarter-over-quarter to $359M.
Based on Tamarack Advisers's 13F filing for Q2 2020, filed 11 Aug 2020.